Vascular Endothelial Growth Factor – Marker for Proliferation in Thyroid Diseases?

Authors

P. Malkomes, E. Oppermann, W. O. Bechstein, K. Holzer

Affiliation

Department of General Surgery, University Hospital of Frankfurt, Frankfurt, Germany

Key words

- VEGF
- VEGF receptors 1 and 2
- goiter
- recurrent
- multinodular
- Graves' disease

Abstract

Vascular endothelial growth factor (VEGF) is a critical regulator of angiogenesis and is involved in tumor development. To date, the role of VEGF in benign diseases of the thyroid is not well known. The purpose of the present study is to determine the expression of VEGF and its receptors in primary cultures of human thyrocytes.

Methods: 50 patients with uninodular (n=11), multinodular (n=15), recurrent goiter (n=14) and Graves' disease (n=10) were enrolled. Nodular and corresponding paranodular tissue was obtained after surgery and investigated. RNA and protein were extracted from primary thyrocyte cultures. PCR, western blot and ELISA were performed to evaluate VEGF isoforms and VEGF receptor 1 and 2.

Results: Significantly increased transcription and protein expression of VEGF and its receptors were detected in nodular tissue of uninodular and recurrent goiter compared to the corresponding normal tissue. Active secretion of VEGF by thyrocytes was confirmed by ELISA. In multinodular goiter, no difference could be found between nodular and corresponding paranodular tissue in terms of expression of VEGF or its receptors. Furthermore, we found the highest levels of VEGF and its receptors in tissue obtained from patients with Graves' disease.

Conclusion: Increased expression of VEGF and its receptors might be crucial in the proliferation of thyrocytes and therefore may contribute to the development of goiter and goiter recurrence.

received 20.04.2012
first decision 17.08.2012
accepted 24.09.2012

Bibliography

DOI <http://dx.doi.org/10.1055/s-0032-1327634>
Exp Clin Endocrinol Diabetes 2013; 121: 6–13
© J. A. Barth Verlag in
Georg Thieme Verlag KG
Stuttgart · New York
ISSN 0947-7349

Correspondence

P. Malkomes
Department of General Surgery
University Hospital of Frankfurt
Theodor-Stern Kai 7
60590 Frankfurt
Germany
Tel.: +49/69/6301 4177
Fax: +49/69/6301 5854
Patrizia.Malkomes@kgu.de

Introduction

In 1989 vascular endothelial growth factor (VEGF) was identified as an angiogenic factor [1]. VEGF is a potent stimulator of endothelial cell growth and a critical regulator of both physiological and pathological angiogenesis [2].

VEGF binds to 2 different tyrosine kinase receptors VEGFR-1 (flt-1) and VEGFR-2 (flk-1/KDR), mainly expressed on endothelial cells [3].

VEGFR-1 may play a more regulatory role in angiogenesis, whereas VEGFR-2 is responsible for signaling [4]. In addition, VEGF mediates inflammatory reactions [5].

Via a paracrine mechanism VEGF signaling plays a critical role in tumor angiogenesis, hence, high expression of VEGF and its receptors was shown in a number of human cancers such as gastric cancer [6], breast cancer [7], colon cancer [8], ovarian cancer [9] and prostate cancer [10]. Increased expression of VEGF was even linked to poor outcome and increased risk for metastasis

and tumor recurrence [11–14]. On the other hand, inhibition of VEGF, its receptors or signaling pathways leads to suppression of tumor angiogenesis and growth [15, 16].

Several studies have demonstrated expression of VEGF and its receptors in benign and malignant thyroid tissue [17–19].

High expression of VEGF in thyroid cancer was found to be correlated with advanced tumor stage, lymph node metastasis and increased risk of recurrence [20–22]. Therefore, VEGF inhibitors are approved for the treatment of advanced thyroid cancers [23].

Furthermore, VEGF seems to be involved in goiter development by inducing endothelial cell proliferation and angiogenesis. Recently, in clinical studies it was demonstrated, that treatment with tyrosine kinase inhibitors leads to hypothyroidism in over 40% of patients, indicating a functional role of the VEGF signaling pathway even in normal thyroid tissue [24, 25].

Table 1 Primer sequences for RT-PCR and expected sizes.

Target genes	Sequence of forward and reverse primer (5'-3')	Size (bp)
VEGF-A	5'-TGC CTT GCT GCT CTA CCT CC-3'	VEGF ₁₂₁ -410
	5'-TCA CCG CCT CGG CTT GTC AC-3'	VEGF ₁₄₅ -480
		VEGF ₁₆₅ -540
		VEGF ₁₈₉ -610
		VEGF ₂₀₉ -660
VEGFR-1	5'-GAT GTT GAG GAA GAG GAG GAT T-3' 5'-AAG CTA GTT TCC TGG GGG TAT A-3'	1 100
VEGFR-2	5'-GAT GTG GTT CTG AGT CGG TCT-3' 5'-CAT GGC TCT GCT TCT CCT TTG-3'	560
GAPDH	5'-ATC TTC CAG GAG CGA GAT CC-3' 5'-ACC ACT CAC ACG TTG GCA GT-3'	509
TPO	5'-AGA TCT GCT GAG CAT CAT TG-3' 5'-CAT CAG GAG CTC AGA ATA GCG-3'	330
TSHR	5'-TAC TTC AGT CCA AGG ATA TG-3' 5'-GCA AGC TCT GCA TAC TGC TCT-3'	361
Tg	5'-GAT CTT ACT GAG TGG CTA CA-3' 5'-ACT GCA CCG CCT GAT AGT CG-3'	682

To date, the role and expression of VEGF and its receptors in normal and benign diseases of the thyroid have rarely been investigated.

This study was performed to investigate the expression pattern of VEGF and its receptors in thyrocytes from normal thyroid tissue and benign thyroid diseases.

Materials and Methods

Patients

50 patients (♀ = 38, ♂ = 12) were enrolled in the clinical study. The protocol was approved by the ethics committee of the University Hospital of Frankfurt and preoperative written consent was obtained from all patients. The patients were divided into 4 groups according to the diagnosis, 11 patients with uninodular goiter (UN), 15 with multinodular goiter (MN), 10 with Graves' disease (G) and 14 patients with recurrent nodular goiter (R) were operated on and included.

Recurrent goiter was defined as development or regrowth of nodules after the first operation of the thyroid gland as revealed by the patient's history. The indication for reoperation was one or more nodular growths as detected by ultrasound. All patients fulfilled these criteria.

Tissue samples and cell culture

Thyroid tissue was obtained after surgical resection. All tissue samples were examined and characterized by a pathologist and when possible, nodular and adjacent non-tumor or paranodular tissues were acquired. In the case of Graves' disease only paranodular tissue was investigated.

The thyroid tissue was minced into small fragments, washed 3 times with HBSS (Hank's balanced salt solution) containing 50 U/ml penicillin and 50 µg/ml streptomycin followed by enzymatic dissociation with 246 U/ml collagenase I for 60–90 min at 37 °C. After digestion, thyrocytes were filtered through a 100 µm nylon mesh (Becton Dickinson; Heidelberg, Germany), pelleted and washed with HBSS.

Thyrocytes were resuspended and counted in Neubauer counting chamber before plating. Cell viability was assessed using trypan blue exclusion (>98%). Thyrocytes were plated at a den-

sity of 50000 cells/well in 6-well plates and were cultured in DMEM supplemented with 10% fetal calf serum, 200 mM Hepes, 50 U/ml penicillin and 50 µg/ml streptomycin. The monocultures were maintained in a standard humidified incubator at 37 °C in a 5% CO₂ atmosphere. On day 1 medium was changed to remove cell debris, on day 4 harvesting was performed. Thyrocyte culture by this procedure has no detectable stromal or endothelial contamination, as attested to by immunohistochemistry and PCR.

Immunofluorescence

Primary thyrocyte cultures were washed with PBS (phosphate buffered saline) and fixed with ice cold acetone for 10 min. After fixation, cells were washed again followed by incubation with primary antibody for 60 min at 4 °C. Primary antibodies were as follows: mouse monoclonal anti-cytokeratine 18 (clone Ks18.04) and 19 (clone Ks19.10) (Progen Biotechnik; Heidelberg, Germany, diluted 1:2), mouse monoclonal anti-fibroblast antibody (Acris antibodies; Hiddenhausen, Germany, diluted 1:100), mouse anti-von Willebrand factor (Dako; Hamburg, Germany, diluted 1:50). After incubation with primary antibodies, cultures were washed twice with wash buffer (0.5% BSA in PBS without Ca++ and Mg++) followed by incubation with secondary antibody for 60 min at 4 °C (NL493 [NorthernLights] – conjugated donkey anti-mouse IgG, diluted to 1:100, (R&D Systems; Wiesbaden-Nordenstadt, Germany). All antibodies were diluted with 0.5% BSA (bovine serum albumin) in PBS. Cell cultures were rinsed 3 times in wash buffer and finally mounted with Prolong antifade Kit (Molecular Probes; Eugene, Oregon). Staining was visualized microscopically by Zeiss Z-1 Observer (Zeiss; Göttingen, Germany). A negative control was also carried by incubating cell cultures with mouse IgG1 (Dako Cytomation, Denmark). All controls were consistently negative.

RNA isolation, cDNA synthesis, semiquantitative RT-PCR, quantitative PCR

Total RNA was extracted using RNeasy kit (Qiagen GmbH; Hilden, Germany) according to the manufacturer's instructions. cDNA was synthesized from 1 µg of total RNA with Oligo (dT) Primer using AffinityScript QPCR cDNA synthesis kit (Stratagene; CA, USA) according to the manufacturer's instructions. Thyroid peroxidase (TPO), TSH receptor (TSHR), Thyroglobulin (Tg), VEGF-A and VEGFR-1 and -2 transcripts were analyzed by performing reverse-transcriptase PCR (RT-PCR) (Table 1). RNA amount and RNA quality were analyzed using Nanovue (GE Healthcare, USA) and Bioanalyzer (Agilent Technologies, USA) respectively. Semi-quantitative RT-PCR was carried out in a 50 µl reaction mixture for each assay containing 1 µl of DNA template, 5 µl of 10× Titanium Taq PCR Buffer, 1 µl of 50× Titanium Taq DNA polymerase (Takara Bio Europe/Clontech; Saint Germain-en-Laye, France), 1 µl of dNTPs (10 mM of each dATP, dCTP, dGTP, dTTP from Takara Bio Europe/Clontech) and 1 µl of primer mix – 50 pmol, of each forward and reverse primer (Table 1) using a Tpersonal Thermocycler (Biomtra GmbH; Goettingen, Germany). PCR parameters were as follows: initial denaturation at 95 °C for 5 min followed by 35 cycles 30s denaturation at 95 °C; 30s of annealing at 64 °C for VEGF-A, VEGFR-1, and VEGFR-2, 58 °C for GAPDH and 55 °C for TPO, TSHR and Tg; 30s elongation at 72 °C and, finally, a further elongation step at 72 °C for 10 min. Ethidium bromide stained amplified fragments were separated by agarose gel electrophoresis (2%), visualized and

Table 2 Primers for QPCR from SABiosciences.

Target genes	Accession number	Reference Position	Size (bp)
VEGF-A	NM 003376	2649	183
VEGFR-1	NM 002019	5144	58
VEGFR-2	NM 002253	629	151
beta-Actin	NM 0011013	1222	191

analyzed by Gel Doc 100 with molecular analyst software (Bio-Rad Laboratories; Munich, Germany).

Densitometric analysis was performed and signal was evaluated as area (mm²). GAPDH was used as housekeeping gene and a 100bp DNA ladder was used as molecular weight marker.

The results were confirmed by real-time quantitative PCR (QPCR) using RT² SYBR-Green/Rox qPCR master mix and gene specific primers (Table 2) (both from SABioscience, USA) according to the manufacturer's protocol. Amplification of genes was performed using MX3005P (Stratagene, USA). 100 ng of cDNA was used in qPCR reaction in duplicates. The dissociation curve was checked at the end of each PCR reaction. GAPDH and β -Actin were used as housekeeping genes and for normalization. Gene expression (fold change) was calculated using $\Delta\Delta C_t$ method after normalizing nodular tissue with each corresponding paranodular or normal adjacent tissue.

Protein isolation and western blot

Thyroidocytes cultures were rinsed twice with ice-cold PBS and lysed for 10 min on ice in lysis buffer (50 mM HEPES, 200 mM NaCl, 0.2 mM MgSO₄, 0.4 mM phenylmethylsulfonyl fluoride, 2 % Triton-X-100, 10 μ g/mL leupeptine, 10 μ g/mL aprotinin, 0.02 % soybean trypsin inhibitor, 0.2 mM ortho-vanadate (Sigma-Aldrich; Taufkirchen, Munich, Germany). Cell lysates were centrifuged for 10 min at 12 000 $\times$ g at 4 °C. Protein concentration of the supernatants was determined by Coomassie Plus protein assay kit (Pierce; Rockford, IL, USA) and were measured spectrophotometrically at 595 nm by Tecan Infinite® M 200 microplate reader (Tecan-Deutschland; Crailsheim, Germany). Protein was denatured in Laemmli sample buffer (Bio-Rad Laboratories; Munich, Germany) with β -mercaptoethanol (Sigma; Taufkirchen, Germany), boiled for 5 min, transferred on ice and subjected to sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) (50 μ g per lane). PeqGold prestained protein marker IV (Peqlab Biotechnologie GmbH; Erlangen, Germany) was used as molecular weight standards. After separation, protein was transferred to a polyvinylidene difluoride membrane (Hybond P; GE Healthcare; Munich, Germany). Blots were blocked with 10 % low-fat milk for 1 h at room temperature followed by incubation with primary antibodies from Santa Cruz Biotechnology (rabbit polyclonal VEGF [total protein], 1:200; rabbit polyclonal VEGFR-1, 1:200; mouse polyclonal VEGFR-2, clone A-3, 1:200 and mouse monoclonal β Actin, clone AC-15, 1:1000; Sigma) overnight at 4 °C. Blots were then washed 3 $\times$ with Towbin buffer with 0.5 % Tween 20 followed by incubation for 30 min with secondary antibody from Millipore GmbH; Schwalbach/Ts, Germany (polyclonal goat antirabbit IgG, 1:5000; goat anti-mouse IgG, 1:5000, both HRP conjugated) at room temperature. All antibodies were diluted in Towbin Buffer with 0.5 % Tween 20 and 0.5 % bovine serum albumin. Blots were then washed and incubated with ECL (Enhanced Chemiluminescence-ECL detection kit from GE Healthcare; Munich, Germany) and exposed to ECL Hyperfilm (GE healthcare), developed in Curix 60 (Agfa;

Dusseldorf, Germany) and documented by Gel Doc 100. β Actin was used as loading control.

ELISA

Cell culture supernatant was quantified using VEGF ELISA-kit (R&D systems; Wiesbaden-Nordenstadt, Germany). The assay was done according to the manufacturer's instructions. Briefly, 200 μ l samples (1:30), standard, and controls were dispensed into microplate wells precoated with anti-VEGF monoclonal antibody, and then incubated for 120 min at room temperature. After incubation, the wells were washed 5 times and 50 μ l of horse radish peroxidase (HRP) conjugated VEGF was added and incubated for 60 min at room temperature. After 5 washes, 100 μ l of chromogenic enzyme substrate solution was added and incubated for 30 min at RT; 50 μ l stop solution was added and spectrophotometrically measured using Infinite® M 200 microplate reader (Tecan-Deutschland; Crailsheim, Germany) at 405 nm. The sample concentration was calculated based on standard concentrations.

Statistical analysis

Data were analyzed using commercially available software Bias for Windows, Version 8.3.7 (H. Ackermann, Johann-Wolfgang Goethe University, Department of Mathematics). Data are presented as means $\pm$ SEM. Non-parametric tests were used due to irregularly distributed data. The groups were compared using Kruskal-Wallis' test. Paired data (nodular and paranodular tissue) were analyzed using Wilcoxon's test. Statistical significance was achieved at $p < 0.05$.

Results

Characterization of thyroidocyte cultures

The primary cell cultures showed the typical morphology of thyroidocytes on microscopic examination, i.e., small, elongated cells arranged as cellular isles (Fig. 1a, b).

Immunohistochemical staining demonstrated the cells to be positive for cytokeratin 18 (Fig. 1c, d) and so to be of epithelial origin. The cells were negative for cytokeratin 19, including fibroblasts specific antigen and Factor VIII (von Willebrand factor), showing no contamination of stromal and endothelial cells, yielding primary thyroidocyte culture purity of greater than 98 %.

In addition, using RT-PCR all cell cultures were positive for thyroid peroxidase (TPO), TSH receptor (TSHR) and thyroglobuline (Tg), namely indicating the presence of thyroidocytes (Fig. 1e).

mRNA expression of VEGF-A, VEGFR-1 and -2 in human thyroidocytes

VEGF-A isoforms were expressed by 99 % of all thyroidocyte cultures. Here expression of VEGF₁₄₅ was significantly higher in nodular tissue from uninodular goiter compared with corresponding normal tissue (VEGF₁₄₅ = 70 $\pm$ 7 counts/mm² [UN] vs. 46 $\pm$ 7 counts/mm² [P]; $p < 0.05$) (Fig. 2a). In recurrent goiter we found higher amounts of VEGF₁₄₅ mRNA in nodular tissue compared to paranodular tissue, but without statistical significance (Fig. 2c). VEGF-R1 and -R2 were significantly increased in nodular vs. paranodular tissue, as shown in uninodular goiter (VEGF-R1 = 479 $\pm$ 68 counts/mm² [UN] vs. 133 $\pm$ 47 counts/mm² [P]; $p < 0.05$; VEGF-R2 = 710 $\pm$ 72 counts/mm² [UN] vs. 361 $\pm$ 52 counts/mm² [P]; $p < 0.05$) (Fig. 2a) and recurrent

Fig. 1 Characterization of primary culture of thyrocytes. **a** Primary thyrocyte culture appearing in clusters on day 1, **b** that reach 95% confluency on day 4 (both 10X). **c** Immunofluorescence staining in primary culture of thyrocytes showing positive cytokeratin 18 **d** and negative isotype control. **e** RT-PCR confirmed the presence of thyrocyte specific markers TSHR, TPO and Tg.

goiter ($\text{VEGF-R1} = 428 \pm 46 \text{ counts/mm}^2$ [UN] vs. $72 \pm 20 \text{ counts/mm}^2$ [P]; $p < 0.05$; $\text{VEGF-R2} = 617 \pm 56 \text{ counts/mm}^2$ [UN] vs. $174 \pm 45 \text{ counts/mm}^2$ [P]; $p < 0.05$) (◉ Fig. 2c).

In Graves' disease we found the highest levels of VEGF_{145} , VEGFR-1 and -2 mRNA compared to the paranodular tissue of the other 3 groups, but without reaching statistical significance (◉ Fig. 2d).

Interestingly, in tissue from patients with multinodular goiter we did not find any significant difference in the expression levels of VEGF and its receptors between nodular and paranodular tissue (◉ Fig. 2b).

The results of RT-PCR were confirmed by performing QPCR. The results are presented as fold change after normalizing nodular tissue with each corresponding paranodular tissue (◉ Table 3a),

as well as after normalizing paranodular tissue of Graves' disease with paranodular tissue of the other 3 groups (◉ Table 3b).

Protein expression of VEGF (total), VEGFR-1 and -2 in human thyrocytes

The VEGF protein was highly expressed in all cell cultures obtained. Furthermore, expression of the receptor proteins was demonstrated in over 90% of the isolated thyrocytes. In uninodular and recurrent goiter, protein expression of VEGF was higher in nodular compared to paranodular tissue as shown in ◉ Fig. 3a. The same results were detected for protein expression of VEGFR-1 and VEGFR-2 (◉ Fig. 3a).

Interestingly, again in multinodular goiter we could not find any difference in protein expression between paranodular and nodular tissue as seen at mRNA level (◉ Fig. 3a).

Fig. 2 Analysis of VEGF₁₄₅, VEGFR-1 and -2 in primary culture of thyrocytes by RT-PCR. **a–c** Expression in nodular tissue of uninodular, multinodular and recurrent goiter (UN, MN, R) vs. their corresponding paranodular tissue (P). Depicted were 5 representative bands from each group. **d** Expression in paranodular tissue of Graves' disease (G) vs. paranodular tissue of uninodular, multinodular and recurrent goiter (UNP, MNP, RP). Depicted was 1 representative band from each group.

a) Nodular tissue vs. paranodular tissue			
Group	VEGF	VEGFR-1	VEGFR-2
UN	+ 15,78 (upregulation)	+ 10,28 (upregulation)	+ 8,28 (upregulation)
MN	+ 1,57 (no regulation)	- 1,64 (no regulation)	+ 1,26 (no regulation)
R	+ 41,53 (upregulation)	+ 28,44 (upregulation)	+ 8,06 (upregulation)
b) Graves' disease vs. paranodular tissue of UN, MN, R			
Group	VEGF	VEGFR-1	VEGFR-2
UNP	+ 3,34 (upregulation)	+ 8,11 (upregulation)	+ 2,26 (upregulation)
MNP	+ 1,43 (no regulation)	3,18 (upregulation)	+ 1,68 (no regulation)
RP	+ 19,29 (upregulation)	+ 14,32 (upregulation)	+ 30,91 (upregulation)

Table 3 Results of QPCR (fold change).

In tissue from Graves' disease we found the highest protein levels of VEGF, VEGFR-1 and -R2. Protein expression of VEGF and VEGFR-1 was significantly increased in comparison to the paranodular tissue of the other 3 groups (VEGF = $0.7 \pm [G]$ vs. $0.5 \pm [UN]$; $0.31 [MN]$; $0.32 [R]$; $p < 0.05$; VEGFR-1 = $0.7 \pm [G]$ vs. $0.36 [UN]$; $0.19 [MN]$; $0.2 [R]$; $p < 0.05$) (• **Fig. 3b**).

Secretion of VEGF by human thyrocytes

All primary cell cultures secreted VEGF protein in the supernatant. The secretion level of VEGF was higher in nodular tissue of patients with recurrent goiter compared to paranodular tissue, without reaching statistical significance (• **Fig. 4**). Again, the highest levels of VEGF were measured in tissue obtained from Graves' disease patients.

Discussion

VEGF, as an angiogenic factor, has been implicated in tumor angiogenesis and in progression of different malignant tumors. Therefore, it is important to investigate its role in thyroid cancer. So far, elevated VEGF expression seems to be associated with higher risk of metastasis, of recurrence and with a poor outcome in thyroid cancer [26]. To date, the expression of VEGF in normal thyroid tissue and its role in the development of goiter and Graves' disease is not well determined.

In the present study, we were able to demonstrate co-expression of VEGF and its receptors VEGFR-1 and -2 in normal human thyrocytes and in benign diseases of the thyroid. In addition, we detected active secretion of VEGF protein by thyrocytes in the supernatant and measured higher concentrations of VEGF protein in nodular tissue of uninodular and recurrent goiter compared to the corresponding normal tissue. Furthermore, the present data demonstrate large amount of VEGF protein in nodular and paranodular tissue of multinodular goiter, that might contribute to the proliferating effect on thyrocytes and its involvement in goiter development.

These findings contradict previous studies, which reported weak expression of VEGF in benign nodules of the thyroid with no differences between normal thyroid tissue and benign adenomas [27,28]. Itoh et al. did not even find any expression of VEGF in normal thyroid tissue and only negative or weak expression in adenomatous goiter [29]. These discrepancies may be explained by the methodological approach used. In previous studies, fresh frozen tissue or formalin-fixed paraffin-embedded tissue was primarily used for the investigation while our study examined pure cultures of freshly isolated thyrocytes, thus, excluding possible endothelial contamination and antigen masking of targets of interest due to formalin-fixation. With regards to the expression of the VEGF receptors, only immunohistochemistry staining of VEGF receptors expression on human thyrocytes of benign thyroid diseases has been shown

Fig. 3 Protein expression of VEGF, VEGFR-1 and -2 of cellular lysates from primary culture of thyrocytes analyzed by western blotting. Depicted was 1 representative band from each group. **a** Expression in nodular (UN, MN, R) vs. their corresponding paranodular tissue (P). **b** Paranodular tissue of Graves' disease (G) vs. paranodular tissue of uninodular, multinodular and recurrent goiter (UNP, MNP, RP).

Fig. 4 VEGF expression in supernatant of primary culture of thyrocytes from nodular and paranodular tissue determined by ELISA. n (nodular = 38; paranodular = 36), results are expressed as mean $\pm$ SEM.

so far. Jebreel et al. reported no differences in VEGFR-1 and -2 expression between the different thyroid pathologies, so the author suggested that up-regulation of VEGF and not of its receptors was important in the development of thyroid diseases [30]. In contrast to our findings, we demonstrated significantly higher expression of the 2 receptors in nodular tissue of uninodular and recurrent goiter compared to corresponding normal tissue both in mRNA and protein level. These results might indicate, that not only up-regulation of VEGF, but also up-regulation of its receptors plays a critical role in the development of goiter. In addition to receptor expression, we were able to detect significant amount of VEGF in the supernatant of thyrocytes culture.

Consistent with our data, Sato et al. reported high levels of VEGF in cyst fluid of thyroid nodules. They postulated that VEGF was secreted by thyrocytes and that it was involved in the pathogenesis of cyst fluid accumulation [31].

In the present study, we were able to detect an active secretion of VEGF by human thyrocytes and simultaneous expression of both VEGF receptors. This coexpression of VEGF and its receptors raises the possibility that VEGF may act in an autocrine loop in thyrocytes, as observed previously in thyroid cancer [32]. Perhaps, an autocrine stimulation plays a crucial role in proliferation of thyrocytes and such up-regulation of the VEGF signaling might be involved in the development of nodular goiter. Besides, high levels of VEGF and its receptors in recurrent nodules may pose potential risk for the development of goiter recurrence.

It is also known, that autocrine stimulation of VEGF receptors leads to enhanced tumor growth [33]. This mechanism, initiated by increased VEGF expression, may also be involved in the growth of thyroid nodules and goiter recurrence.

In our study, we did not find any differences in gene or protein expression of VEGF and its receptors between nodular and paranodular tissue of patients with multinodular goiter, but instead detected an increased concentrations of the growth factor in both tissues. Therefore, we postulated, that in multinodular goiter the entire tissue of the thyroid gland might be pathologically altered and are not only limited in the circumscribed nodules. Although the cause of recurrence might be of multifactorial origin, elevated expression of VEGF and its receptors might also contribute to the high rate of recurrence of over 20% of multinodular goiter after subtotal resection [34–36]. Our findings are also in accord with clinical studies which assumed an involvement of the whole thyroid parenchyma in benign disease and therefore, recommended total thyroidectomy as a suitable treatment [37].

Furthermore, we examined tissue from 10 patients with Graves' disease. In the literature, contradictory data are reported on VEGF expression in this autoimmune disease of the thyroid gland. However, several authors could not detect any expression of VEGF in Graves' disease in immunohistochemical staining [29] or only at lower levels compared to neoplastic tissue [30] and so argued that VEGF signaling plays only a minor role in the development of autoimmune disease of the thyroid gland. On the other hand, Iitaka et al. reported increased serum VEGF levels in patients with Graves' disease compared to healthy persons [38]. Furthermore, studies demonstrated a positive correlation between VEGF levels and increased vascular density in Graves' disease [39] as well as strong expression of VEGF in hyperplastic follicular cells and surrounding capillaries [40], indicating a link between epithelial function and microcirculation.

In concordance with these data, we have detected in our study high levels of VEGF and its receptors both in mRNA and protein in monocultures of thyrocytes obtained from patients with Graves' disease. Here, we have shown that the expression was significantly increased compared with the other groups.

These results may indicate that VEGF is involved in the pathogenesis of Graves' disease and may have an influence on both epithelial proliferation and thyroid microcirculation, causing a typical hypervascularization and hyperplasia seen in this autoimmune disease. Moreover, this might be a first hint, that VEGF might also be involved in the control of thyroid function. Besides the up-regulation of VEGF in goiter, the present study was able to confirm the expression of VEGF and its receptors in

normal thyroid tissue. Clinical studies have also reported, that over 40% of patients treated with tyrosine kinase inhibitors (TKI) developed hypothyroidism [24,25]. Recently Sato et al. reported a sonographically detectable atrophy of the thyroid gland caused by sunitinib therapy [41]. One hypothesis for TKI-related hypothyroidism is inhibition of the VEGF-pathway resulting in reduction of capillary blood flow. These observations and data may signify that VEGF signaling might participate not only in thyroid hyperplasia but is also essential in normal thyroid function as well as physiological proliferation of thyrocytes.

Conclusion

In summary, our study showed an increased expression of VEGF and its receptors in nodular tissue of uninodular and recurrent goiter as well as in the entire tissue of multinodular goiter and Graves' disease. Therefore, we hypothesized that VEGF may be involved in the proliferation of thyrocytes and its up-regulation via autocrine mechanism might contribute to the development of thyroid nodules and hyperplasia of the thyroid gland. Although, it is very likely that goiter recurrence is of multifactorial origin, VEGF may serve as a proliferation marker in thyroid disease and may be used as a possible target for future strategies for the treatment of neoplastic and autoimmune diseases of the thyroid. Until now, the exact role of VEGF in thyroid function remains to be determined. Hence, more future studies are eminent to elucidate the role of VEGF in thyroid diseases.

Conflict of interest: None.

References

- Ferrara N, Henzel WJ. Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells. *Biochem Biophys Res Commun* 1989; 161 (2): 851–858
- Ferrara N, Houck K, Jakeman L et al. Molecular and biological properties of the vascular endothelial growth factor family of proteins. *Endocr Rev* 1992; 13 (1): 18–32
- Ferrara N. Vascular endothelial growth factor: basic science and clinical progress. *Endocr Rev* 2004; 25 (4): 581–611
- Ferrara N, Davis-Smyth T. The biology of vascular endothelial growth factor. *Endocr Rev* 1997; 18 (1): 4–25
- Takahashi H, Shibuya M. The vascular endothelial growth factor (VEGF)/VEGF receptor system and its role under physiological and pathological conditions. *Clin Sci (Lond)* 2005; 109 (3): 227–241
- Kakeji Y, Koga T, Sumiyoshi Y et al. Clinical significance of vascular endothelial growth factor expression in gastric cancer. *J Exp Clin Cancer Res* 2002; 21 (1): 125–129
- Scott PA, Smith K, Poulson R et al. Differential expression of vascular endothelial growth factor mRNA vs protein isoform expression in human breast cancer and relationship to eIF-E4. *Br J Cancer* 1998; 77 (12): 2120–2128
- Konno H, Tanaka T, Baba M et al. Quantitative analysis of vascular endothelial growth factor in colon cancer. Clinical and experimental. *Eur Surg Res* 1998; 30 (4): 273–278
- Hatenbach EM, Olson TA, Goswitz JJ et al. Vascular endothelial growth factor (VEGF) expression and survival in human epithelial ovarian carcinomas. *Cancer Lett* 1997; 121 (2): 169–175
- Strohmeier D, Strauss F, Rössing C et al. Expression of bFGF, VEGF and c-met and their correlation with microvessel density and progression in prostate carcinoma. *Anticancer Res* 2004; 24 (3a): 1797–1804
- Maeda K, Chung YS, Ogawa Y et al. Prognostic value of vascular endothelial growth factor expression in gastric carcinoma. *Cancer* 1996; 77 (5): 858–863
- Feng Y, Wang W, Hu J et al. Expression of VEGF-C and VEGF-D as significant markers for assessment of lymphangiogenesis and lymph node metastasis in non-small cell lung cancer. *Anat Rec (Hoboken)* 2010; 293 (5): 802–812
- Xiang Z, Zeng Z, Tang Z et al. Increased expression of vascular endothelial growth factor-C and nuclear CXCR4 in hepatocellular carcinoma is correlated with lymph node metastasis and poor outcome. *Cancer J* 2009; 15 (6): 519–525
- Morales-Gutiérrez C, Abad-Barahona A, Moreno-González E et al. Tumour VEGF/non tumour VEGF protein expression ratio as a biomarker for survival in colorectal cancer patients. *Eur J Surg Oncol* 2011; 37 (6): 526–531
- Valachis A, Polyzos NP, Patsopoulos NA et al. Bevacizumab in metastatic breast cancer: a meta-analysis of randomized controlled trials. *Breast Cancer Res Treat* 2010; 122 (1): 1–7
- Yakes FM, Chen J, Tan J et al. Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth. *Mol Cancer Ther* 2011; 10 (12): 2298–2308
- Klein M, Picard E, Vignaud JM et al. Vascular endothelial growth factor gene and protein: strong expression in thyroiditis and thyroid carcinoma. *J Endocrinol* 1999; 161 (1): 41–49
- Turner HE, Harris AL, Melmed S et al. Angiogenesis in endocrine tumors. *Endocr Rev* 2003; 24 (5): 600–632
- Capp C, Wajner SM, Siqueira DR et al. Increased expression of vascular endothelial growth factor and its receptors, VEGFR-1 and VEGFR-2, in medullary thyroid carcinoma. *Thyroid* 2010; 20 (8): 863–871
- Erdem H, Gündoğdu C, Sipal S. Correlation of E-cadherin, VEGF, COX-2 expression to prognostic parameters in papillary thyroid carcinoma. *Exp Mol Pathol* 2011; 90 (3): 312–317
- Karaca Z, Tanrıverdi F, Unluhizarci K et al. VEGFR1 expression is related to lymph node metastasis and serum VEGF may be a marker of progression in the follow-up of patients with differentiated thyroid carcinoma. *Eur J Endocrinol* 2011; 164 (2): 277–284
- Lennard CM, Patel A, Wilson J et al. Intensity of vascular endothelial growth factor expression is associated with increased risk of recurrence and decreased disease-free survival in papillary thyroid cancer. *Surgery* 2001; 129 (5): 552–558
- Deshpande H, Roman S, Thumar J et al. Vandetanib (ZD6474) in the treatment of medullary thyroid cancer. *Clin Med Insights Oncol* 2011; 5: 213–221
- Mannavola D, Coco P, Vannucchi G et al. A novel tyrosine-kinase selective inhibitor, sunitinib, induces transient hypothyroidism by blocking iodine uptake. *J Clin Endocrinol Metab* 2007; 92 (9): 3531–3534
- Brown RL. Tyrosine kinase inhibitor-induced hypothyroidism: incidence, etiology, and management. *Target Oncol* 2011; 6 (4): 217–226
- Hsueh C, Lin JD, Wu IC et al. Vascular endothelial growth factors and angiopoietins in presentations and prognosis of papillary thyroid carcinoma. *J Surg Oncol* 2010; 103 (5): 395–399
- Bunone G, Vigneri P, Mariani L et al. Expression of angiogenesis stimulators and inhibitors in human thyroid tumors and correlation with clinical pathological features. *Am J Pathol* 1999; 155 (6): 1967–1976
- Tanaka K, Kurebayashi J, Sonoo H et al. Expression of vascular endothelial growth factor family messenger RNA in diseased thyroid tissues. *Surg Today* 2002; 32 (9): 761–768
- Itoh A, Iwase K, Jimbo S et al. Expression of vascular endothelial growth factor and presence of angiovascular cells in tissues from different thyroid disorders. *World J Surg* 2010; 34 (2): 242–248
- Jebreel A, England J, Bedford K et al. Vascular endothelial growth factor (VEGF), VEGF receptors expression and microvascular density in benign and malignant thyroid diseases. *Int J Exp Pathol* 2007; 88 (4): 271–277
- Sato K, Miyakawa M, Onoda N et al. Increased concentrations of vascular endothelial growth factor/vascular permeability factor in cyst fluid of enlarging and recurrent thyroid nodules. *J Clin Endocrinol Metab* 1997; 82 (6): 1968–1973
- Vieira JM, Santos SC, Espadinha C et al. Expression of vascular endothelial growth factor (VEGF) and its receptors in thyroid carcinomas of follicular origin: a potential autocrine loop. *Eur J Endocrinol* 2005; 153 (5): 701–709
- Fan F, Wey JS, McCarty MF et al. Expression and function of vascular endothelial growth factor receptor-1 on human colorectal cancer cells. *Oncogene* 2005; 24 (16): 2647–2653
- Vaiman M, Nagibin A, Hagag P et al. Subtotal and near total versus total thyroidectomy for the management of multinodular goiter. *World J Surg* 2008; 32 (7): 1546–1551
- Snook KL, Stalberg PL, Sidhu SB et al. Recurrence after total thyroidectomy for benign multinodular goiter. *World J Surg* 2007; 31 (3): 593–598
- Moalem J, Suh I, Duh QY. Treatment and prevention of recurrence of multinodular goiter: an evidence-based review of the literature. *World J Surg* 2008; 32 (7): 1301–1312

- 37 Basili G, Biagini C, Manetti A *et al.* Risk of recurrence following partial thyroidectomy for benign lesions. Report of 58 patients 15–25 years after surgery. *Minerva Chir* 2003; 58 (3): 321–329
- 38 Iitaka M, Miura S, Yamanaka K *et al.* Increased serum vascular endothelial growth factor levels and intrathyroidal vascular area in patients with Graves' disease and Hashimoto's thyroiditis. *J Clin Endocrinol Metab* 1998; 83 (11): 3908–3912
- 39 Nagura S, Katoh R, Miyagi E *et al.* Expression of vascular endothelial growth factor (VEGF) and VEGF receptor-1 (Flt-1) in Graves disease possibly correlated with increased vascular density. *Hum Pathol* 2001; 32 (1): 10–17
- 40 Gérard AC, Denef JF, Many MC *et al.* Relationships between cell division, expression of growth factors and microcirculation in the thyroids of Tg-A2aR transgenic mice and patients with Graves' disease. *J Endocrinol* 2003; 177 (2): 269–277
- 41 Sato S, Muraishi K, Tani J *et al.* Clinical characteristics of thyroid abnormalities induced by sunitinib treatment in Japanese patients with renal cell carcinoma. *Endocr J* 2010; 57 (19): 873–880